JACOB MALONE: Open Payments
NPI 1851043947 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,360 in 55 payments from 16 companies in 2025. Trend: 2023 $1,071 · 2024 $775 · 2025 $1,360
Food & beverage: $1,360
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 6 | $257 |
| E.R. Squibb & Sons, L.L.C. | 8 | $254 |
| Edwards Lifesciences Corporation | 1 | $160 |
| Daiichi Sankyo Inc. | 6 | $105 |
| Novartis Pharmaceuticals Corporation | 5 | $85 |
| Merck Sharp & Dohme LLC | 5 | $83 |
| Novo Nordisk Inc | 5 | $82 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $77 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 4 | $66 |
| Amgen Inc. | 3 | $47 |
Products named: AMVUTTRA, SAPIEN 3 Ultra RESILIA, CAMZYOS, INJECTAFER, ONPATTRO, LEQVIO, Wegovy, Kerendia.
Industry payments across OK — which companies pay providers there.
